

CONTRACT R&D



Our assays are developed as a two-step, single use test that simply requires the addition of the sample on to the cartridge. The assay is then inserted into our Agilis Reader for the analyte measurement and analysis to take place.

If you are looking to bring a new diagnostic product to market, or even improve an existing platform, we can help.

As a business we offer:

- OEM development
- Rapid PoC diagnostics
- Reader based customised assay systems
- A variety of applications and business sectors
- Fully quantitative tests
- Small batch and full-scale manufacture

OUR PROVEN 5-STAGE DEVELOPMENT PROCESS



PROOF OF PRINCIPLE



FEASIBILITY



OPTIMISATION



VERIFICATION &
TRANSFER TO
MANUFACTURE



VALIDATION

Our partnerships also include technology licencing, and we can move forward with the manufacture of your assay, if required.

Our Strengths

- Thorough communication
- Development continuity
- Dedicated science and delivery team
- Technology is universally adaptable

Assay Development

The reagents we use for the electrochemical immunoassay are of key importance to our assay technology. We use silver nanoparticles as the signalling system. The key benefit is that the detection limits are much improved while sample volumes required for analysis are reduced.

The flexibility of our technology is achieved because the analyte capture method is based on an "immune complex" being formed in exactly the same manner as in any immunoassay. These reduced sample volumes together with the improved detection limits mean that miniaturisation of the system is much easier, whilst still achieving a fully quantitative sample analysis.



For more information on our please visit our website
www.agplusdiagnostics.com

